» Articles » PMID: 28416033

Pharmacological Treatment of Mixed States

Overview
Journal CNS Spectr
Specialties Neurology
Psychiatry
Date 2017 Apr 19
PMID 28416033
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Mixed states in bipolar disorder have been neglected, and the data concerning treatment of these conditions have been relatively obscure. To address this, we systematically reviewed published pharmacological treatment data for "mixed states/episodes" in mood disorders, including "with mixed features" in DSM-5. We searched PubMed, MEDLINE, The Cochrane Library, clinicaltrials.gov, and controlled-trials.com (with different combinations of the following keywords: "mixed states/features," "bipolar," "depressive symptoms/bipolar depression," "manic symptoms," "treatment," "DSM-5") through to October 2016. We applied a quality-of-evidence approach: first-degree evidence=randomized placebo-controlled studies of pharmacological interventions used as monotherapy; second-degree evidence=a similar design in the absence of a placebo or of a combination therapy as a comparative group; third-degree evidence=case reports, case series, and reviews of published studies. We found very few primary double-blind, placebo-controlled studies on the treatment of mixed states: the preponderance of available data derives from subgroup analysis performed on studies that originally involved manic patients. Future research should study the effects of treatments in mixed states defined using current criteria.

Citing Articles

Treatment of mixed depression with theta-burst stimulation (TBS): results from a double-blind, randomized, sham-controlled clinical trial.

Tavares D, Suen P, Rodrigues Dos Santos C, Moreno D, Valiengo L, Klein I Neuropsychopharmacology. 2021; 46(13):2257-2265.

PMID: 34193961 PMC: 8580982. DOI: 10.1038/s41386-021-01080-9.


Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features: Analysis of a Randomized Placebo-Controlled Trial.

Singh M, Pikalov A, Siu C, Tocco M, Loebel A J Child Adolesc Psychopharmacol. 2020; 30(10):590-598.

PMID: 32392455 PMC: 7757594. DOI: 10.1089/cap.2020.0018.


Treatment of Mixed Features in Bipolar Disorder: an Updated View.

Chakrabarty T, Keramatian K, Yatham L Curr Psychiatry Rep. 2020; 22(3):15.

PMID: 32025903 DOI: 10.1007/s11920-020-1137-6.


Mixed States: Modelling and Management.

Malhi G, Fritz K, Elangovan P, Irwin L CNS Drugs. 2019; 33(4):301-313.

PMID: 30712252 DOI: 10.1007/s40263-019-00609-3.


Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Yatham L, Kennedy S, Parikh S, Schaffer A, Bond D, Frey B Bipolar Disord. 2018; 20(2):97-170.

PMID: 29536616 PMC: 5947163. DOI: 10.1111/bdi.12609.